Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.275    0.025 (2.04%)
Bid:
1.20
Ask:
1.35
Spread: 0.15 (12.50%)
Market Cap: £20.07m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Director/PDMR Shareholding

18 Jul 2019 07:00

RNS Number : 9066F
Genedrive PLC
18 July 2019
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 51,250 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at an average price of 19p per share.

 

Following these purchases, Dr Gilham is interested in 317,674 Ordinary Shares, 0.93% of the issued share capital of the Company.

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Ian Gilham

 

 

2.

Reason for the notification

a.

Position/status

Non-Executive Chairman

a.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

genedrive plc

b.

LEI

213800ZYODIRZ87Y4K14

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

b.

Nature of the transaction

Purchase

c.

Price(s) and volume(s)

 

Price(s)

Volume(s)

19p

51,250

 

d.

Aggregated information

· Aggregated volume

· Price

 

 

N/A

 

e.

Date of the transaction

2019-07-17; UTC time

f.

Place of the transaction

London Stock Exchange, AIM

 

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO

 

Matthew Fowler: CFO

 

Peel Hunt LLP

+44 (0)207 418 8900

James Steel

 

Oliver Jackson

 

 

Stanford Capital Partners Limited

 

+44 (0)20 3815 8880

 

Patrick Claridge / John Howes

 

 

 

Walbrook PR Ltd (Media Relations & Investor Relations)

 

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAEXXFSSNEAF
Date   Source Headline
1st Oct 202512:30 pmRNSHolding(s) in Company
30th Sep 20259:52 amRNSHolding(s) in Company
29th Sep 20255:03 pmRNSHolding(s) in Company
29th Sep 20253:00 pmRNSPublication of Circular and Notice of GM
29th Sep 20257:00 amRNSResult of Retail Offer
24th Sep 20257:00 amRNSCompletion of Placing
23rd Sep 20255:03 pmRNSProposed Retail Offer
23rd Sep 20254:59 pmRNSProposed Placing to raise a minimum of £3 million
23rd Sep 20259:00 amRNSHolding(s) in Company
23rd Sep 20259:00 amRNSHolding(s) in Company
15th Sep 20254:24 pmRNSResult of General Meeting
10th Sep 20254:15 pmRNSHolding(s) in Company
10th Sep 20254:15 pmRNSHolding(s) in Company
29th Aug 202512:00 pmRNSProposed Share Capital Reorganisation & GM
21st Aug 20257:00 amRNSScotland’s Public Health Minister visit
14th Aug 202510:35 amRNSComment re: Share Price Movement
11th Aug 20257:00 amRNSTrading update
30th May 20257:00 amRNSBlock Listing Returns
30th May 20257:00 amRNSCE-certification
13th May 20257:00 amRNSCYP2C19-ID Kit used to support expansion
2nd May 20251:30 pmRNSCYP2C19 ID Kit CE-IVD certification update
2nd Apr 20257:01 amRNSAdditional grant funding under DEVOTE programme
2nd Apr 20257:00 amRNSReceipt of R&D tax credit
1st Apr 20257:00 amRNSResult of RetailBook Offer
27th Mar 20253:30 pmRNSRetailBook Offer
27th Mar 20253:29 pmRNSHalf-year Report
27th Mar 20253:28 pmRNSEquity Fundraise
17th Mar 202511:04 amRNSScottish Government testing programme investment
14th Mar 20257:00 amRNSCYP2C19-ID Kit adopted for routine clinical use
30th Dec 202411:54 amRNSResult of AGM
27th Dec 20247:00 amRNSGenedrive® CYP2C19-ID Kit performance published
20th Dec 202412:16 pmRNSGrant of Options
20th Dec 202412:12 pmRNSDirector/PDMR Shareholding
5th Dec 20243:00 pmRNSPosting of annual report and notice of AGM
29th Nov 20241:00 pmRNSBlock listing returns
29th Nov 20247:00 amRNSFinal Results
22nd Nov 20247:00 amRNSNotice of Results
21st Nov 202411:06 amRNSNIHR and OLS Funding Package
4th Nov 20241:29 pmRNSScottish Health Technology Group publications
21st Oct 20243:22 pmRNSDirector Declaration
15th Aug 202410:39 amRNSDirector/PDMR Shareholding
12th Aug 20247:00 amRNSFirst UK commercial sales of the CYP2C19-ID Kit
6th Aug 20247:00 amRNSDirectorate Change
31st Jul 20247:00 amRNSNICE recommends CYP2C19-ID Kit in final guidance
15th Jul 20247:00 amRNSBreakthrough Device Designation from the U.S. FDA
27th Jun 20249:28 amRNSShort extension to NICE publication date
25th Jun 20247:00 amRNSHolding(s) in Company
24th Jun 202411:13 amRNSHolding(s) in Company
24th Jun 202411:12 amRNSHolding(s) in Company
24th Jun 202411:11 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.